Clinical Trials Logo

Hepatitis C clinical trials

View clinical trials related to Hepatitis C.

Filter by:

NCT ID: NCT04405024 Recruiting - Hepatitis C Clinical Trials

Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients

HOSPI-VHC
Start date: September 21, 2020
Phase: N/A
Study type: Interventional

The Ministry of Health has set the target of eradicating hepatitis C (HCV) in France by 2025. The goal is to validate the feasibility and value of conducting routine HCV screening in hospitalized patients.

NCT ID: NCT04395118 Withdrawn - Clinical trials for Hepatocellular Carcinoma

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

STOP-HCC
Start date: August 15, 2020
Phase: N/A
Study type: Interventional

The investigators will conduct a randomized controlled trial comparing two strategies to promote HCV screening, follow-up testing, and treatment among Parkland patients who are 18 years or older who have elevated liver functioning test (LFT) results: in reach with electronic medical record alerts and provider education vs. combination of in reach and provider education plus mailed outreach and patient navigation.

NCT ID: NCT04391985 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

enrolled participants were treated orally with SOF plus a fixed dose combination of OBV/PTV/r plus RBV.

NCT ID: NCT04389268 Completed - Hepatitis C Clinical Trials

P300 in Early Cognitive Impairment in Hepatitis C Virus

Start date: February 1, 2018
Phase:
Study type: Observational

Approximately 50% of patients with hepatitis C have complaints of fatigue and cognitive deficits even before the development of significant hepatic impairment.

NCT ID: NCT04387539 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants

Start date: March 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)

NCT ID: NCT04387526 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Start date: April 1, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.

NCT ID: NCT04385407 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Start date: April 2015
Phase: Phase 2
Study type: Interventional

A total of 201 participants with chronic HCV GT4 infection were allocated into two groups. One group participants were treated with SOF plus RBV (24 weeks). The second group was treated with SOF plus SMV (12 weeks).

NCT ID: NCT04382937 Completed - Clinical trials for Chronic Hepatitis C Virus Infection

Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection

Start date: January 12, 2016
Phase: Phase 3
Study type: Interventional

Primary objective: To demonstrate non-inferiority in sustained virologic response (SVR, undetectable HCV RNA at Follow up week 12) between PEG-Intron 1.5 µg per kg SC Q1W + Ribavirin 800-1400 mg PO daily and P1101 400 µg SC Q2W + Ribavirin 800-1400 mg PO daily for the treatment of chronic HCV genotype 2 infection

NCT ID: NCT04382404 Completed - Clinical trials for Hepatitis C, Chronic

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

Start date: October 22, 2020
Phase: Phase 1
Study type: Interventional

A single-arm, single-center, open label Phase 1 study of a 12-week course of Sofosbuvir (SOF)/Velpatasvir (VEL) in 10 HCV-infected pregnant women 1 that will evaluate the plasma pharmacokinetic parameters of SOF/VEL administered during pregnancy and compare them to those of a historical cohort of nonpregnant women.

NCT ID: NCT04382339 Completed - Clinical trials for Hepatitis C Virus Infection

Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

HCV
Start date: March 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 participants